Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence

被引：26

作者：

Akazawa, Yuko ^{[1
]}

Fukuda, Daisuke ^{[2
]}

Fukuda, Yutaka ^{[2
]}

机构：

[1] Nagasaki Univ Hosp, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[2] Fukuda Yutaka Surg Clin, Nagasaki, Japan

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2016年 / 9卷 / 06期

关键词：

Vonoprazan; H; pylori; PPI; Takecab; potassium-competitive acid blocker; P-CAB; TAK-438; COMPETITIVE ACID BLOCKER; TRIPLE THERAPY; TAK-438; VONOPRAZAN; GASTRIC-CANCER; CLARITHROMYCIN; EFFICACY; TOLERABILITY; RESISTANCE; INFECTION; SAFETY;

D O I：

10.1177/1756283X16668093

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H. pylori eradication. The latest literature and our clinical experience have shown that vonoprazan-based therapies have satisfactory eradication rates. Additionally, vonoprazan-based therapies are associated with similar rates of adverse events as standard triple therapies with conventional proton-pump inhibitors.

引用

页码：845 / 852

页数：8

共 50 条

[31] VONOPRAZAN-BASED DUAL THERAPY WITH AMOXICILLIN IS AS EFFECTVE AS THE TRIPLE THERAPY FOR THE ERADICATION OF H-PYLORI
Furuta, Takahisa
Yamade, Mihoko
Uotani, Takahiro
Kagami, Takuma
Suzuki, Takahiro
Tani, Shinya
Hamaya, Yasushi
Iwaizumi, Moriya
Osawa, Satoshi
Sugimoto, Ken
GASTROENTEROLOGY, 2018, 154 (06) : S927 - S927
[32] Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
Suzuki, Sho
Ishibashi, Fumiaki
Gotoda, Takuji
INTERNAL MEDICINE, 2023, 62 (16) : 2299 - 2300
[33] Vonoprazan-based Eradication Therapy for H. Pylori Infection in Patients Allergic to Penicillin
Furuta, Takashisa
Yamade, Mihoko
Kagami, Takuma
Ichikawa, Hitomi
Suzuki, Takahiro
Hamaya, Yasushi
Iwaizumi, Moriya
Osawa, Satoshi
Ken, Sugimoto
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S485 - S485
[34] Vonoprazan-Based Dual Therapy With Amoxicillin Is as Effective as the Triple Therapy for Eradication of H. pylori
Furuta, Takahisa
Yamade, Mihoko
Uotani, Takahiro
Kagami, Takuma
Suzuki, Takahiro
Hamaya, Yasushi
Iwaizumi, Moriya
Osawa, Satoshi
Sugimoto, Ken
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S672 - S672
[35] Vonoprazan for Helicobacter pylori eradication
Baker, Holly
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (02): : 93 - 93
[36] Vonoprazan-based eradication therapy for H. pylori infection in patients allergic to penicillin
Furuta, Takahisa
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 82 - 82
[37] Vonoprazan Dual and Triple Therapy for Helicobacter pylori Eradication
Chey, William D.
Megraud, Francis
Laine, Loren
Lopez, Luis J.
Hunt, Barbara
Smith, Neila
Leifke, Eckhard
Knipfer, Nancianne
Howden, Colin W.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S634 - S634
[38] Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
Sugimoto, Mitsushige
Yamaoka, Yoshio
FRONTIERS IN PHARMACOLOGY, 2019, 9
[39] A comparison of Helicobacter pylori eradication therapy with vonoprazan and conventional therapy
Mado, Kazunari
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 90 - 90
[40] VONOPRAZAN-BASED DUAL THERAPY WITH AMOXICILLIN IS AS EFFECTIVE AS THE TRIPLE THERAPY FOR ERADICATION OF H. PYLORI.
Furuta, T.
Kagami, T.
Suzuki, T.
Ichikawa, H.
Yamade, M.
Umemura, K.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S29 - S29

← 1 2 3 4 5 →